This page shows the latest Odefsey news and features for those working in and with pharma, biotech and healthcare.
Once-daily, single-tablet Odefsey reduces risks of side effects such as renal and bone toxicity. ... Gilead Sciences has added to its portfolio of HIV drugs in Europe after getting EMA approval for Odefsey, a three-drug combination based on its new
Descovy was approved by the US FDA earlier this month, while a three-drug combination called Odefsey (emtricitabine, rilpivirine and TAF) - a follow-up to its $1.4bn Complera product - was
Descovy is the third TAF-based HIV drug in Gilead's portfolio - joining its other once-daily treatments Genvoya and Odefsey - and adds to the biopharmaceutical firm's dominance in the
FDA gives Odefsey the green light. . Gilead Sciences has added another new product to its HIV franchise following FDA approval of Odefsey, a three-drug regimen taken as a single small
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...